Biocryst Pharmaceuticals
Open
$8.69
Prev. Close
$8.69
High
$8.72
Low
$8.68
Market Snapshot
$2.18B
-4.8
-0.43
$450.71M
435
BioCryst Pharmaceuticals, Inc. is a biotechnology company. The company is headquartered in Durham, North Carolina and currently employs 435 full-time employees. Its marketed products include oral, once-daily ORLADEYO for the prevention of hereditary angioedema (HAE) attacks and RAPIVAB (peramivir injection) for the treatment of acute uncomplicated influenza in the United States. Its other products and product candidates include BCX10013, RAPIACTA (peramivir injection), PERAMIFLU (peramivir injection), and early-stage discovery programs. BCX10013, is a potent and specific Factor D inhibitor. RAPIACTA focuses on uncomplicated seasonal influenza. The RAPIVAB (peramivir injection) is approved in the United States for the treatment of acute uncomplicated influenza for patients six months and older. Its portfolio also includes navenibart, which is a late-stage, long-acting plasma kallikrein inhibitor. The company has also obtained an early-stage program for atopic dermatitis, STAR0310.
BioCryst Pharmaceuticals, Inc. is a biotechnology company. The company is headquartered in Durham, North Carolina and currently employs 435 full-time employees. Its marketed products include oral, once-daily ORLADEYO for the prevention of hereditary angioedema (HAE) attacks and RAPIVAB (peramivir injection) for the treatment of acute uncomplicated influenza in the United States. Its other products and product candidates include BCX10013, RAPIACTA (peramivir injection), PERAMIFLU (peramivir injection), and early-stage discovery programs. BCX10013, is a potent and specific Factor D inhibitor. RAPIACTA focuses on uncomplicated seasonal influenza. The RAPIVAB (peramivir injection) is approved in the United States for the treatment of acute uncomplicated influenza for patients six months and older. Its portfolio also includes navenibart, which is a late-stage, long-acting plasma kallikrein inhibitor. The company has also obtained an early-stage program for atopic dermatitis, STAR0310.
Recently from Cashu
Biocryst Pharmaceuticals Advances Hereditary Angioedema Treatments with ORLADEYO and Navenibart Initiatives
Biocryst Pharmaceuticals reaffirms its dedication to advancing treatment options for hereditary angioedema through two key initiatives: the established ORLADEYO treatment and the investigational monoc…
BioCryst Pharmaceuticals Prepares to Showcase Advances in Hereditary Angioedema at EAACI 2026
BioCryst Pharmaceuticals (Ticker: BCRX) showcases its commitment to advancing treatment for hereditary angioedema as it prepares for the EAACI Annual Meeting, scheduled for June 12-15, 2026, in Istanb…
BioCryst Pharmaceuticals Licenses Navenibart for HAE Treatment in Europe to Neopharmed Gentili
BioCryst Pharmaceuticals, a company listed on Nasdaq (Ticker: BCRX), has recently made headlines through a strategic licensing agreement with Neopharmed Gentili. This agreement specifically pertains t…
BioCryst Pharmaceuticals' Q4 Earnings Show Commitment to Rare Disease Treatment Innovations
BioCryst Pharmaceuticals: Advancements in Rare Disease Treatments Highlighted in Q4 Earnings Report BioCryst Pharmaceuticals (NASDAQ:BCRX) presents a compelling narrative in its fourth-quarter earning…